Niki Biosolutions Inc (NIKI)

$7.99 -0.27 (-3.27%)
Market Cap 6.73M
Revenue (ttm) 0.00
Net Income (ttm) -1.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.25
Volume 15,500
Avg Vol 101,638
Day's Range N/A - N/A
Shares Out 814,000.00
Stochastic %K 20%
Beta 0.39
Analysts Strong Buy
Price Target N/A

Company Profile

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infecti...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 951 2222
Address:
116 Village Boulevard, Suite 200, Princeton, United States
JimmyOcarri
JimmyOcarri Aug. 17 at 9:27 PM
$NIKI $ADVB $ASTC $MI s
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:37 PM
$ADVB $NXPL $NIKI $BULL $MI gen•
0 · Reply
ATrain01
ATrain01 Aug. 16 at 1:33 PM
$NIKI This will be HUGE!!! By $NIKI executing the merger with DiamiR it results in direct exposure to Biogen, Eli Lilly and other giants!!! Too much catalyst to ignore.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 15 at 3:25 PM
$NIKI Specialized Alzheimer’s/neuro biomarker laboratory + proprietary microRNA IP + existing academic network + demonstrated pharma customer revenue + clinical diagnostics upside + extremely concentrated share ownership. The merger gave a start to the business to keep scaling and hit big deals!
0 · Reply
BULLNATION_
BULLNATION_ Aug. 15 at 3:18 PM
$NIKI USC ATRI (Alzheimer's Therapeutics Research Institute) isn’t some obscure academic lab. It’s a major Alzheimer’s clinical-trial organization whose consortium is led with Harvard and Mayo Clinic and works across academia and industry on intervention research. 🔥 NIKI has proven to work with big leagues academy and wouldnt surprise to see some big news coming out very soon! 👀 Anyone shorting this will suffer a lot.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 14 at 8:06 PM
$NIKI Go to your weekend knowing this... @BULLNATION_ only gives out real gems! Soon deal with $70M to $130M market cap company🔥👀 NIKI/DiamiR is already deeply connected to this ecosystem and their collaborations: University of Pennsylvania USC Alzheimer’s Therapeutic Research Institute Weill Cornell Medicine Brain Health Imaging Institute NYU School of Medicine And previous collaborators include: Washington University Alzheimer’s Disease Research Center UCSD Alzheimer’s Disease Cooperative Study Biomarker Core Montefiore/Albert Einstein New York Blood Center These institutions have supplied DiamiR with well-characterized plasma samples and associated clinical data. $WETO $STKH $DFSC $SXTC
0 · Reply
BULLNATION_
BULLNATION_ Aug. 13 at 4:01 PM
$NIKI Okay Mr. Pandemic Stimulus investor
0 · Reply
texmade2
texmade2 Aug. 13 at 2:36 PM
$NIKI you rich off this junk yet, LOL NOT VERY MANY FALLING FOR THIS SCAM.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 13 at 1:28 PM
$NIKI Crazy how SEC allowed a scam to do a successful merger... SEC is a scam 3 Insiders own 75% of company. Look for any small cap company that insiders own so much. If management were scammers, wouldnt they hold near 2% of OS knowing the company is a scam? You will just get burn here very bad.
0 · Reply
giancachimi
giancachimi Aug. 13 at 7:58 AM
$FGL $NIKI $LGHL $WLDS $LNKS
0 · Reply
Latest News on NIKI
Aptorum Group Provides Update on DiamiR Biosciences Merger

Jul 16, 2026, 11:00 AM EDT - 4 weeks ago

Aptorum Group Provides Update on DiamiR Biosciences Merger

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference

Jul 8, 2026, 8:00 AM EDT - 6 weeks ago

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers

Statement in Response to Silver Elephant's News Release Dated June 17, 2026

Jun 18, 2026, 5:29 PM EDT - 2 months ago

Statement in Response to Silver Elephant's News Release Dated June 17, 2026

Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences

Jun 10, 2026, 8:00 AM EDT - 2 months ago

Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

Feb 2, 2026, 8:00 AM EST - 7 months ago

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Nov 19, 2025, 8:00 AM EST - 9 months ago

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

Oct 10, 2025, 9:54 AM EDT - 11 months ago

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Oct 9, 2025, 8:55 AM EDT - 11 months ago

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:00 AM EDT - 1 year ago

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Aug 21, 2025, 7:07 AM EDT - 1 year ago

DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aug 4, 2025, 8:15 AM EDT - 1 year ago

Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Jul 16, 2025, 8:38 AM EDT - 1 year ago

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 16, 2025, 12:27 PM EDT - 1 year ago

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Jan 8, 2025, 11:30 AM EST - 1 year ago

Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Jan 2, 2025, 10:55 AM EST - 1 year ago

Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Dec 20, 2024, 4:00 PM EST - 1 year ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Apr 30, 2024, 9:15 AM EDT - 2 years ago

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Mar 6, 2024, 8:00 AM EST - 2 years ago

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Dec 22, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Dec 21, 2023, 4:30 PM EST - 2 years ago

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Nov 16, 2023, 11:00 AM EST - 2 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aug 10, 2023, 2:57 AM EDT - 3 years ago

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Jun 22, 2023, 8:00 AM EDT - 3 years ago

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Jun 9, 2023, 4:30 PM EDT - 3 years ago

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 5, 2023, 4:31 PM EDT - 3 years ago

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

May 1, 2023, 8:00 AM EDT - 3 years ago

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Apr 28, 2023, 9:44 AM EDT - 3 years ago

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

Mar 17, 2023, 8:15 AM EDT - 3 years ago

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)

ASPI

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Mar 3, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Mar 2, 2023, 7:30 AM EST - 3 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Feb 10, 2023, 4:30 PM EST - 3 years ago

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Feb 6, 2023, 10:08 AM EST - 3 years ago

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Aptorum Group Announces 1-for-10 Reverse Stock Split

Jan 20, 2023, 8:22 AM EST - 3 years ago

Aptorum Group Announces 1-for-10 Reverse Stock Split

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Jan 4, 2023, 9:00 AM EST - 3 years ago

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Dec 22, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Dec 16, 2022, 8:00 AM EST - 3 years ago

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Dec 9, 2022, 7:00 AM EST - 4 years ago

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Nov 25, 2022, 8:30 AM EST - 4 years ago

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Nov 25, 2022, 8:00 AM EST - 4 years ago

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Nov 18, 2022, 5:30 PM EST - 4 years ago

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Nov 8, 2022, 6:00 AM EST - 4 years ago

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Sep 30, 2022, 7:42 PM EDT - 4 years ago

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Sep 15, 2022, 8:07 AM EDT - 4 years ago

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Sep 15, 2022, 7:00 AM EDT - 4 years ago

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aug 25, 2022, 8:31 PM EDT - 4 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 17, 2022, 8:13 AM EDT - 4 years ago

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

JimmyOcarri
JimmyOcarri Aug. 17 at 9:27 PM
$NIKI $ADVB $ASTC $MI s
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:37 PM
$ADVB $NXPL $NIKI $BULL $MI gen•
0 · Reply
ATrain01
ATrain01 Aug. 16 at 1:33 PM
$NIKI This will be HUGE!!! By $NIKI executing the merger with DiamiR it results in direct exposure to Biogen, Eli Lilly and other giants!!! Too much catalyst to ignore.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 15 at 3:25 PM
$NIKI Specialized Alzheimer’s/neuro biomarker laboratory + proprietary microRNA IP + existing academic network + demonstrated pharma customer revenue + clinical diagnostics upside + extremely concentrated share ownership. The merger gave a start to the business to keep scaling and hit big deals!
0 · Reply
BULLNATION_
BULLNATION_ Aug. 15 at 3:18 PM
$NIKI USC ATRI (Alzheimer's Therapeutics Research Institute) isn’t some obscure academic lab. It’s a major Alzheimer’s clinical-trial organization whose consortium is led with Harvard and Mayo Clinic and works across academia and industry on intervention research. 🔥 NIKI has proven to work with big leagues academy and wouldnt surprise to see some big news coming out very soon! 👀 Anyone shorting this will suffer a lot.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 14 at 8:06 PM
$NIKI Go to your weekend knowing this... @BULLNATION_ only gives out real gems! Soon deal with $70M to $130M market cap company🔥👀 NIKI/DiamiR is already deeply connected to this ecosystem and their collaborations: University of Pennsylvania USC Alzheimer’s Therapeutic Research Institute Weill Cornell Medicine Brain Health Imaging Institute NYU School of Medicine And previous collaborators include: Washington University Alzheimer’s Disease Research Center UCSD Alzheimer’s Disease Cooperative Study Biomarker Core Montefiore/Albert Einstein New York Blood Center These institutions have supplied DiamiR with well-characterized plasma samples and associated clinical data. $WETO $STKH $DFSC $SXTC
0 · Reply
BULLNATION_
BULLNATION_ Aug. 13 at 4:01 PM
$NIKI Okay Mr. Pandemic Stimulus investor
0 · Reply
texmade2
texmade2 Aug. 13 at 2:36 PM
$NIKI you rich off this junk yet, LOL NOT VERY MANY FALLING FOR THIS SCAM.
0 · Reply
BULLNATION_
BULLNATION_ Aug. 13 at 1:28 PM
$NIKI Crazy how SEC allowed a scam to do a successful merger... SEC is a scam 3 Insiders own 75% of company. Look for any small cap company that insiders own so much. If management were scammers, wouldnt they hold near 2% of OS knowing the company is a scam? You will just get burn here very bad.
0 · Reply
giancachimi
giancachimi Aug. 13 at 7:58 AM
$FGL $NIKI $LGHL $WLDS $LNKS
0 · Reply
beppels
beppels Aug. 13 at 7:21 AM
$FGL BEPPELS WL 13.08.: - $FGL, 0.96 $, 920 k float, halted up overnite, no dilution below 6.87 $, pm gapper! ✅ - $NIKI, 9.25 $, 1.17 mln float, china bio merger from APM funded for 9.5 years! ✅ - $LGHL, 0.78 $, 920 k float, 21.8 $ cash per share, grossly undervalued! ✅ - $WLDS, 2.95 $, 2.17 mln float, 6.95 $ cash per share, 911 % ctb, 0 borrow! ✅ - $LNKS, 1.05 $, 1.33 mln float, 20.9 $ cash per share! ✅ Also watch GITS, ZCMD, BRAI, UPC! 👀 🔥 👀
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 13 at 6:45 AM
$FGL $LGHL $NIKI $VBIO 10X potential.
0 · Reply
texmade2
texmade2 Aug. 12 at 9:41 PM
$NIKI always be aware
0 · Reply
drweinerdog1
drweinerdog1 Aug. 12 at 9:27 PM
$NIKI .90 spread right now
0 · Reply
BULLNATION_
BULLNATION_ Aug. 12 at 8:12 PM
$NIKI UPDATE NOW!! ORANGE ALERT!!!!!! All metrics coming together for a massive run ahead! Be aware that our system is built to detect high price metrics way ahead of market digestion. PD: Orange is the strongest signal prior to full green, set up is imminent! @BULLNATION_ Checkout our call records, we are into a huge move ahead! $BOXL $RMCF $XHLD
0 · Reply
BULLNATION_
BULLNATION_ Aug. 12 at 2:10 PM
$NIKI IT'S YELLOW ALERT!!! Price structure, pressure, and quantum metrics are bullish now! Ready for $17 and $43 test! Do not wait until news because the gap up on news day will be huge! Get in on first signals! More DD bellow! $BOXL $OFAL $RMCF $BIVI
0 · Reply
BULLNATION_
BULLNATION_ Aug. 11 at 1:23 PM
$NIKI Many will see this once it is already up 300% and will be chasing, @BULLNATION_ record of finding gems is amazingly high! We HIGHLY RECOMMEND taking a look at this stock before it launches its news! 🔥 $ELPW $NCRA $WXM
0 · Reply
_ProfessorGamma
_ProfessorGamma Aug. 10 at 4:34 PM
$NIKI I'm not folding here
1 · Reply
BULLNATION_
BULLNATION_ Aug. 10 at 1:35 PM
$NIKI HOTTEST SWING ON MARKET! Can easily become the multi-day runner you have been chasing lately but have not got in on time! $STKH $JWEL $SDOT $DFNS
0 · Reply
TapeDripTom
TapeDripTom Aug. 9 at 7:24 AM
$GAUZ $NIKI Keep a close watch on AIFA! Had a strong c lose Friday, plus the DD below isa real strong case why AIFA might go wild next week.
0 · Reply
ATrain01
ATrain01 Aug. 8 at 6:25 PM
$GAUZ $LBGJ $ONFO agree…and I wouldn’t count out $NIKI either…8K is out and they are rapidly moving forward!
0 · Reply
BULLNATION_
BULLNATION_ Aug. 7 at 10:25 PM
$NIKI DO NOT FORGET! 🔥800k float 🔥3 Insiders own 75% 🔥Ready to get Big Pharma deals for diagnostics/lab services 🔥All merger shares restricted until Q2 2027 - No diluting on the next run! $SDOT $NAMI $YJ $MB
2 · Reply